Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 30Nivolumab 10Cyclophosphamide 9fludarabine 7atezolizumab 7aldesleukin 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Carboplatin 5Biopsy 5cemiplimab 4Trastuzumab 4Interleukin-2 4Docetaxel 4Cisplatin 4spartalizumab 3durvalumab 3Specimen Handling 3Polymerase Chain Reaction 3Gene Expression Profiling 3Fulvestrant 3Fluorouracil 3tisotumab vedotin 2tislelizumab 2palbociclib 2fludarabine phosphate 2entinostat 2avelumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Brentuximab Vedotin × Head & Neck × Clear all
NCT04254107 2025-02-10

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Seagen Inc.

Phase 1 Terminated
133 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡